Investing Management Resources in Basic Research and Advanced Products and Businesses with a Long-Term Perspective
First written in FY2017-Q1. 10 of 18 entries say "Restated". Latest entry: FY2026.
115 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「The company launched “MicrobialTrack,” cloud-based software for microbial identification using MALDI-TOF MS, powered by the industry's largest database covering 85,000 microbial species, including unculturable and difficult-to-culture species.」
Resources devoted to research and development and product commercialization were developed into specific new products, including cloud software using a database of 85,000 microbial species, AI and automated diagnostics, next-generation analytical instruments, and electron microscopes. - FY2025AdvancedAnnual report
「The Company developed the world's first element-selective gas chromatograph-mass spectrometer, ELEM-SPOT, which uses proprietary element-selective technology to detect only oxygen- and nitrogen-containing components in biofuels.」
R&D investment in future technologies and products developed into specific results, including an analyzer for biofuels, new LC-MS products, robotic automated sample-preparation equipment, ultra-high-speed video cameras, and scanning electron microscopes. - FY2024AdvancedAnnual report
「This software incorporates an algorithm trained on Ajinomoto Co.,Inc.'s LC analysis data and automatically performs analyses with approximately 90% agreement with expert analysts, reducing analysis time by approximately 75% compared with conventional methods.」
Investment in R&D resulted in a specific product outcome: automation of LC analysis using AI algorithms. The company also disclosed metrics showing an approximately 90% matching rate and an approximately 75% reduction in analysis time. - FY2023AdvancedAnnual report
「In January 2023, the company opened the Shimadzu Tokyo Innovation Plaza to strengthen its application development capabilities.」
Progress in allocating R&D resources to future technologies and products was demonstrated by the opening of new R&D and application development facilities. - FY2021AdvancedAnnual report
「New building of the Fundamental Technology Research Laboratory (SHIMADZU Mirai Co-Creation Lab), building (increase): ¥6.911 billion」
As a specific capital investment in the allocation of resources to research and development with a view to the future, the Company disclosed the development of a new building for the Fundamental Technology Research Laboratory. - FY2020AdvancedAnnual report
「To this end, the Company will make use of its newly opened Healthcare R&D Center, strengthen the functions of innovation centers around the world, and establish a new system for nurturing business seeds.」
Regarding the allocation of resources to growth fields, a healthcare R&D center was opened, and measures to strengthen the functions of innovation centers worldwide and develop business seeds were outlined. - FY2020-Q3RestatedAnnual report
「Investment in growth fields such as “Advanced Healthcare”」
The investment policy for growth fields such as Advanced Healthcare has been reaffirmed. - FY2020-Q2RestatedAnnual report
「Investment in growth fields such as “Advanced Healthcare,”」
The policy of allocating management resources to growth fields such as advanced healthcare continues. - FY2020-Q1RestatedAnnual report
「Investment in growth fields such as “Advanced Healthcare”」
The policy of continuing to invest in growth areas such as Advanced Healthcare has been reconfirmed. - FY2019-Q3RestatedAnnual report
「Investment in growth fields such as “Advanced Healthcare”」
The policy of allocating management resources to growth areas has been reaffirmed. - FY2019-Q2RestatedAnnual report
「Investment in growth fields such as “Advanced Healthcare”」
The policy of allocating management resources to growth areas has been reaffirmed. - FY2019-Q1RestatedAnnual report
「Investment in growth fields such as “Advanced Healthcare”」
The policy of allocating management resources to growth fields continues in the form of investment in areas such as advanced healthcare. - FY2018-Q2RestatedAnnual report
「Investment in growth fields such as “Advanced Healthcare”」
The policy of pursuing future growth through investment in growth areas has been reaffirmed. - FY2018-Q1RestatedAnnual report
「Investment in growth fields such as Advanced Healthcare」
The policy of allocating management resources to future growth areas has been reaffirmed through investments in areas including advanced healthcare. - FY2017RaisedAnnual report
「The company will increase investment in R&D for priority models and capital investment in facilities such as the “Innovation Center,” which serves as an R&D base for promoting open innovation globally.」
The scope of the policy of allocating resources to research and products with a view to the future has been clarified to include increased investment in priority products and the innovation center. - FY2017-Q3RestatedAnnual report
「To fulfill its corporate motto of “contributing to society through science and technology,” the Company invests substantial management resources as a manufacturer providing advanced products and services centered on measuring, medical, aircraft and industrial equipment, for forward-looking basic research and the development, manufacture and marketing of advanced products and businesses,」
The company has reaffirmed its policy of investing management resources with a view to the future, from basic research through product and business development, manufacturing and marketing. - FY2017-Q2RestatedAnnual report
「To fulfill its corporate motto of “contributing to society through science and technology,” the Company invests substantial management resources as a manufacturer providing advanced products and services centered on measuring, medical, aircraft and industrial equipment, for forward-looking basic research and the development, manufacture and marketing of advanced products and businesses,」
The allocation of management resources to research, products and businesses with a view to the future has been reaffirmed. - FY2017-Q1First statedAnnual report
「We are investing significant management resources in basic research and in the development, manufacture, and marketing of advanced products and businesses with a view to the future,」
Describes long-term investment of resources from basic research through development, manufacturing, and marketing.